African Journal of Microbiology Research
Subscribe to AJMR
Full Name*
Email Address*

Article Number - 5198CF762341


Vol.11(2), pp. 38-44 , January 2017
DOI: 10.5897/AJMR2016.8381
ISSN: 1996-0808



Full Length Research Paper

Escherichia coli bacteremia: Clinical features, risk factors and clinical implication of antimicrobial resistance



Fawzia E. Alotaibi*
  • Fawzia E. Alotaibi*
  • Department of Pathology and Laboratory Medicine, College of Medicine, King Saud University and King Saud University Medical City, Riyadh, Saudi Arabia.
  • Google Scholar
Elham E. Bukhari
  • Elham E. Bukhari
  • Department of Paediatric, Infectious Disease, College of Medicine, King Saud University and King Saud University Medical City, Riyadh, Saudi Arabia.
  • Google Scholar







 Received: 13 November 2016  Accepted: 08 December 2016  Published: 14 January 2017

Copyright © 2017 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


Escherichia coli is an important cause of both community acquired (CA) and hospital acquired (HA) bacteremia. A prospective study was conducted at a tertiary care University Hospital from January, 2012 to July 2014, to compare the clinical features, risk factors, outcomes and antimicrobial resistance between E. coli bacteremia acquired from the community (CA) versus E. coli bacteremia acquired from the hospital (HA). Clinical and laboratory data of 171 adult patients with at least one positive blood culture of E. coli were analyzed. Data were collected from patients with significant blood stream infection, using medical and laboratory record files and information from treating medical staff. The overall incidence of extended spectrum beta lactamase (ESBL) infection was high, 67/171 (77.4%). Thirty-eight (40.9%) of the CA isolates were found to produce ESBL, while 28 (35.9%) of the HA isolates were ESBL producers. Patients with CA bacteremia tend to be older than those with HA bacteremia (0.003). Neoplastic diseases (hematological malignancy (<0.001), solid tumors (<0.001)), renal transplantation end stage renal disease (ESRD) (<0.006), and wound infection (<0.001) were the most commonly associated conditions in patients with HA bacteremia. Patients from the community are more likely to present with UTI (<0.001), fever and pyelonephritis (0.001). Both CA and HA E. coli isolates showed the highest sensitivity to imipenem, meropenem and amikacin followed by gentamicin and tazocin. The CA isolates are more susceptible to amikacin, tazocin and ciprofloxacin than the HA isolates. No significant difference in the mortality rate between patients with CA bacteremia and patients who acquire the bacteremia in a hospital setting (0.836) was observed. Clinicians need to be aware of the risk factors and changing pattern of antimicrobial resistance of this pathogen and should consider adequate empirical therapy with coverage of these pathogens for patients with risk factors

Key words: Escherichia coli, community acquired, hospital acquired, bacteremia, blood stream infection.

 

Abbreviation:

CA, Community acquired; HA, hospital acquired; ESBL, extended spectrum beta lactamase; ESRD, end stage renal disease.


Aiken AM, Mturi N, Njuguna P, Mohammed S, Berkley JA, Mwangi I (2011). Risk and causes of paediatric hospital-acquired bacteraemia in Kilifi District Hospital, Kenya: a prospective cohort study. Lancet. 378:2021-2027.
Crossref

 

Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC (2010). Epidemiology of bloodstream infections in patients with hematological malignancies with and without neutropenia. Epidemiol. Infect. 138:1044-1051.
Crossref

 

El-Khizzi NA, Bakheshwain SM (2006). Frequency of extended-spectrum beta-lactamases among Enterobacteriaceae isolated from blood culture in a tertiary care hospital. Saudi Med. J. 27:37-40

 

Hoenigl M, Wagner J, Raggam RB, Prueller F, Prattes J, Eigl S (2014). Characteristics of hospital-acquired and community-onset blood stream infections, South-East Austria. PLoS One. 9:e104702.
Crossref

 

Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E (2005). Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase- producing Enterobacteriaceae: variability by site of infection. Arch. Intern. Med. 165:1375-1380.
Crossref

 

Johnson JR, Clermont O, Menard M, Kuskowski MA, Picard B, Denamur E (2006). Experimental mouse lethality of Escherichia coliisolates, in relation to accessory traits, phylogenetic group, and ecologicalsource. J. Infect. Dis. 194:1141-1150.
Crossref

 

Kader AA, Kumar AK (2004). Frequency of extended spectrum beta-lactamase among multidrug resistant Gram-negative isolates from a general hospital in Saudi Arabia. Saudi Med. J. 25:570-574

 

Kang CI, Cha MK, Kim SH, Ko KS, Wi YM, Chung DR (2013). Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli over a 6-year period. J. Korean Med. Sci. 28:998-1004.
Crossref

 

Khan FY, Elshafie SS, Almaslamani M, Abu-Khattab M, El Hiday AH, Errayes M (2010). Epidemiology of bacteraemia in Hamad general hospital, Qatar: a one year hospital-based study. Travel Med. Infect. Dis. 8:377-387.
Crossref

 

Khanfar HS, Bindayna KM, Senok AC, Botta GA (2009). Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. Infect. Dev. Ctries. 3:295-9.

 

Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD (2008). Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin. Microbiol. Infect. 14:1041-1047.
Crossref

 

Masoud EA, Mahdy ME, Esmat AM (2011). Bacterial Prevalence and Resistance to Antimicrobial Agents in Southwest, Saudi Arabia University, Saudi. Egypt. Acad. J. Biol. Sci. 3:105-111.

 

Memon JI, Rehmani RS, Ahmed MU, Elgendy AM, Nizami IY (2009). Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia. Saudi Med. J. 30:803-8.

 

National Committee for Clinical Laboratory Standards, Wayne P. Performance standards for antimicrobial susceptibility testing. 9th Informational Supplement. National Committee for Clinical Laboratory Standards. 1999:M100-S109.

 

Pitout JD, Hanson ND, Church DL, Laupland KB (2004). Population based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with bla CTX-M genes. Clin. Infect. Dis. 38:1736-1741.
Crossref

 

Pitout JD, Laupland KB (2008). Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166.
Crossref

 

Quirante OF, Cerrato GR, Pardos SL (2011). Risk factors for bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumonia. Braz. J. Infect. Dis.15:370-376.
Crossref

 

Rodrguez-Bano J, Picón E, Gijón P, Hernández JR, Cisneros JM, Pe-a C (2010). Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J. Clin. Microbiol. 48:1726-1731.
Crossref

 

Rodrguez-Bano J, Navarro MD, Romero L, Muniain MA, deCueto M, Glvez J (2008). Risk factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin. Microbiol. Infect. 14:180-183.
Crossref

 

Rodríguez-Bano J, Lopez-Prieto MD, Portillo MM, Retamar P, Natera C, Nuno E, Herrero M (2009). Epidemiology and clinical features of community-acquired, healthcare associated and nosocomial bloodstream infections in tertiary and community hospitals. Clin. Microbiol. Infect. 16:1408-1413.
Crossref

 

Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, de Cueto M, Ríos MJ (2006). Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis. 43:1407-1414.
Crossref

 

Rodríguez-Bano J, Picón E, Gijón P, Hernández JR, Ruíz M, Pe-a C (2010). Spanish Network for Research in Infectious Diseases (REIPI).Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin. Infect. Dis. 50:40-48.
Crossref

 

Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, Golan Y, Noy A, Schwartz D (2002). Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin. Infect. Dis. 34:1431-1439.
Crossref

 

Tenaillon O, Skurnik D, Picard B, Denamur E (2010). The population genetics of commensal Escherichia coli. Nat. Rev. Microbiol. 8:207-217.
Crossref

 

Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B (2008). Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob. Agents. Chemother. 52:3244-3252.
Crossref

 

Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B (2007). Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 51:1987-1994.
Crossref

 

Uslan DZ, Crane SJ, Steckelberg JM, Cockerill FR 3rd, St Sauver JL, Wilson WR (2007). Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Arch. Intern. Med. 167:834-839.
Crossref

 

Wayne P, CLSI (2005). Performance standards for antimicrobial susceptibility testing. 15th informational supplement. Approved standard M100–S15.

 

Williamson DA, Lim A, Wiles S, Roberts SA, Freeman JT (2013). Population-based incidence and comparative demographics of community-associated and healthcare-associated Escherichia coli bloodstream infection in Auckland, New Zealand. BMC Infect. Dis. 13:385.
Crossref

 

Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D (2004). Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J. Antimicrob. Chemother. 54:735-743.
Crossref

 


APA Alotaibi, F. E., & Bukhari, E. E. (2017). Escherichia coli bacteremia: Clinical features, risk factors and clinical implication of antimicrobial resistance. African Journal of Microbiology Research, 11(2), 38-44.
Chicago Fawzia E. Alotaibi and Elham E. Bukhari. "Escherichia coli bacteremia: Clinical features, risk factors and clinical implication of antimicrobial resistance." African Journal of Microbiology Research 11, no. 2 (2017): 38-44.
MLA Fawzia E. Alotaibi and Elham E. Bukhari. "Escherichia coli bacteremia: Clinical features, risk factors and clinical implication of antimicrobial resistance." African Journal of Microbiology Research 11.2 (2017): 38-44.
   
DOI 10.5897/AJMR2016.8381
URL http://academicjournals.org/journal/AJMR/article-abstract/5198CF762341

Subscription Form